Driven by market demand, De Dietrich develops an API production set that enables continuous manufacturing of molecules that require exothermic chemical reactions.
Samsung continues an agreement formerly signed with Glenmark to manufacture Ichnos’ mAb treatment candidate for atopic dermatitis, as the product enters Phase III clinical trials.
Speaking at CPhI 2019, Piramal CCO puts the spotlight on patients who ultimately 'pay the bill,' and explains how this mentality could reshape the CDMO business.
This month’s people on the move includes a new therapeutic lead at Advanced Clinical, with plans to create a network of investigation sites, as well as CEOs at AIT Bioscience and Pharm-Olam, who discuss plans for moving forward.
Vetter recently completed a successful pilot project to automate aspects of its secondary packaging series with the use of a dual-arm robot – which provides a high degree of continuity and precision, says CDMO.
Yourway sets up a new EU-based location to provide storage and distribution services, including secondary packaging capabilities, as Brexit uncertainties abound.
An expansion to BIA Separations' Cornerstone set of processing services for viral vector development adds the use of kryptonase and CIMmultus chromatography device.
Cellectis chooses Lonza to take on the clinical manufacturing of its UCART blood cancer immunotherapy candidates, intended to be marketed as industrialized, readily available CAR-T cells.
Partnering with airlines is essential, says CSafe executive, as the company signs an agreement to use LOT Cargo’s to airplanes to transporttemperature-sensitive biologics.
AstraZeneca is implementing N-Side’s recently launched Suite for Clinical Trials to provide ‘a single source of truth’ for safely supplying trials, as more stakeholders are generating more data.
Almac joins a working group made up of clinical supply chain industry members, in order to contribute to the use case discussion about blockchain technology.
‘Talk to your CDMO early’ is the advice BioConnection gives to developers of biopharmaceuticals, suggesting that they make a reservation to ensure availability.
